4D Molecular Therapeutics (FDMT) AI Stock Analysis

• Market Cap: $196.42M
• Dividend Yield: N/A
• Average Volume (3M): 467.68K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.43
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 227
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.86
• Shares Outstanding: 46,324,642
• 10 Day Avg. Volume: 559,199
• 30 Day Avg. Volume: 467,675
• PEG Ratio: -0.26
• Price to Book (P/B): -2.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.32
• Enterprise Value/Market Cap: 2.63
• Enterprise Value/Revenue: 25.43
• Enterprise Value/Gross Profit: 319.11
• Enterprise Value/Ebitda: -0.76
• 1Y Price Target: $29.40
• Price Target Upside: 582.13% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 51 Neutral
• Price Target: $4.00 ▼(-7.19%Downside)

The overall score is influenced most by the company's financial performance and technical analysis. Financial challenges are a significant risk, with persistent negative income and cash flow issues. However, technical indicators show some positive momentum. Valuation remains a concern due to negative earnings and no dividend yield.

Positive Factors

Clinical Trials

Enrollment for 4FRONT-1 has exceeded projections, indicating increased interest in 4D-150.

Financial Performance

FDMT reiterated its expectations for its cash balance to support operations into 2028, highlighting financial stability.

Product Development

Long-term durability and safety updates for 4D-150 are expected to continue to validate its favorable risk/benefit profile.

Negative Factors

Leadership

The resignation of CFO/CBO Uneek Mehra might indicate potential leadership changes or challenges within the company.

Market Challenges

The recent charitable foundation funding gap impacting wAMD treatments and launch of biosimilars makes the analyst more conservative on the commercial opportunity for now.

Program Delays

4D-175, 4D-725, and 4D-310 remain paused pending additional financing or partnerships, indicating potential delays in these programs.

4D Molecular Therapeutics Business Overview & Revenue Model

Company Description

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

How the Company Makes Money

4D Molecular Therapeutics generates revenue primarily through strategic collaborations, licensing agreements, and partnerships with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, research funding, milestone payments, and royalties based on the success and commercialization of the developed therapies. The company also invests in its own pipeline of gene therapy candidates, aiming to bring them to market, which could provide additional revenue streams through product sales. Furthermore, 4D Molecular Therapeutics may receive government grants and incentives for research and development in genetic therapies.

4D Molecular Therapeutics Financial Statement Overview

Summary

4D Molecular Therapeutics faces significant financial challenges typical of the biotechnology sector, particularly in early-stage development without consistent revenue streams. The balance sheet shows improvement, but the negative income and cash flow trends highlight ongoing operational hurdles. Future success will rely heavily on successful research outcomes and continued access to financing.

Income Statement

The company has experienced erratic revenue trends with significant fluctuations over the years. The lack of revenue in 2024 compared to the previous year denotes a challenging operational environment. Negative net income has been persistent, showcasing difficulties in achieving profitability. Margins are negative, and although the company had some revenue growth in prior years, sustainability remains questionable.

Balance Sheet

The company's balance sheet shows a strong equity base due to significant cash holdings, which is a positive aspect. However, the company's financial stability is undermined by negative equity in previous years. Recent improvements in stockholders' equity and low debt levels indicate improving financial health, but past fluctuations present a risk.

Cash Flow

Cash flow from operations is consistently negative, reflecting ongoing cash burn typical of early-stage biotech companies. While free cash flow remains negative, the increase in financing activities suggests reliance on external funding to sustain operations. Positive trends in financing cash flow are countered by high levels of capital expenditure.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	23.00K	37.00K	20.72M	3.13M	18.04M	13.61M
Gross Profit	1.62M	37.00K	-76.37M	-751.00K	15.02M	-39.43M
EBITDA	-203.17M	-187.84M	-107.12M	-106.15M	-68.31M	-55.22M
Net Income	-176.44M	-160.87M	-100.84M	-101.08M	-68.30M	-56.54M
Balance Sheet
Total Assets	515.73M	560.38M	339.89M	261.85M	353.49M	288.33M
Cash, Cash Equivalents and Short-Term Investments	321.44M	424.88M	288.23M	218.64M	315.43M	276.73M
Total Debt	23.85M	24.61M	14.67M	16.12M	16.45M	0.00
Total Liabilities	46.01M	49.78M	32.06M	30.51M	560.48M	31.94M
Stockholders Equity	469.72M	510.61M	307.83M	-314.49M	-207.00M	256.39M
Cash Flow
Free Cash Flow	-153.49M	-138.37M	-78.56M	-98.22M	-78.24M	-51.91M
Operating Cash Flow	-153.25M	-134.59M	-75.79M	-86.69M	-69.13M	-50.91M
Investing Cash Flow	-7.23M	-302.44M	115.72M	-17.05M	-172.68M	-1.00M
Financing Cash Flow	18.42M	337.25M	156.83M	3.08M	118.09M	278.98M

4D Molecular Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.31
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FDMT, the sentiment is Positive. The current price of 4.31 is above the 20-day moving average (MA) of 4.16, above the 50-day MA of 3.73, and below the 200-day MA of 5.85, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 57.27 is Neutral, neither overbought nor oversold. The STOCH value of 56.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FDMT.

4D Molecular Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SLN	56 Neutral	$268.74M	―	-99.23%	―	-40.10%	-16.60%
RGLS	52 Neutral	$564.95M	―	-53.82%	―	―	44.85%
Sector *	51 Neutral	$7.50B	0.32	-61.87%	2.27%	17.10%	1.59%
FDMT	51 Neutral	$196.42M	―	-32.97%	―	―	―
ADCT	51 Neutral	$277.70M	―	123.38%	―	10.49%	47.31%
FATE	46 Neutral	$128.39M	―	-49.23%	―	105.85%	22.13%
KRRO	45 Neutral	$122.92M	―	-60.22%	―	―	85.19%

4D Molecular Therapeutics Corporate Events

4D Molecular Therapeutics Updates Phase 3 Program for Wet AMD

On June 27, 2025, Uneek Mehra announced his resignation as Chief Financial and Business Officer of 4D Molecular Therapeutics, effective July 15, 2025, to pursue other opportunities. He will continue to provide advisory services until September 2025, ensuring a smooth transition. The company has started searching for a successor. On July 2, 2025, the company provided updates on its Phase 3 program for wet AMD, noting that enrollment for the 4FRONT-1 trial exceeded expectations, leading to an accelerated timeline for topline data in early 2027. Additionally, the 4FRONT-2 trial began ahead of schedule. The company also announced a 25% workforce reduction in July 2025 to streamline operations, resulting in significant cost savings and extending its cash runway into 2028.

The most recent analyst rating on (FDMT) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on 4D Molecular Therapeutics stock, see the FDMT Stock Forecast page.

4D Molecular Therapeutics Holds Annual Stockholders Meeting

On June 17, 2025, 4D Molecular Therapeutics held its Annual Meeting of Stockholders virtually, where 38,470,536 shares were voted on four proposals. The stockholders elected Class II directors, ratified the selection of PricewaterhouseCoopers LLP as the independent auditor, approved executive compensation, and decided to hold annual advisory votes on executive compensation.

The most recent analyst rating on (FDMT) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on 4D Molecular Therapeutics stock, see the FDMT Stock Forecast page.